Type I interferons in anticancer immunity DOI
Laurence Zitvogel, Lorenzo Galluzzi, Oliver Kepp

et al.

Nature reviews. Immunology, Journal Year: 2015, Volume and Issue: 15(7), P. 405 - 414

Published: June 1, 2015

Language: Английский

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients DOI
Roy S. Herbst, Jean‐Charles Soria,

Marcin Kowanetz

et al.

Nature, Journal Year: 2014, Volume and Issue: 515(7528), P. 563 - 567

Published: Nov. 25, 2014

Language: Английский

Citations

4813

Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy DOI Creative Commons
Padmanee Sharma, Siwen Hu‐Lieskovan, Jennifer A. Wargo

et al.

Cell, Journal Year: 2017, Volume and Issue: 168(4), P. 707 - 723

Published: Feb. 1, 2017

Language: Английский

Citations

4410

Elements of cancer immunity and the cancer–immune set point DOI
Daniel S. Chen, Ira Mellman

Nature, Journal Year: 2017, Volume and Issue: 541(7637), P. 321 - 330

Published: Jan. 1, 2017

Language: Английский

Citations

4327

Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response DOI
Peng Jiang, Shengqing Gu, Deng Pan

et al.

Nature Medicine, Journal Year: 2018, Volume and Issue: 24(10), P. 1550 - 1558

Published: Aug. 13, 2018

Language: Английский

Citations

3896

Tumor-Associated Macrophages: From Mechanisms to Therapy DOI Creative Commons

Roy Noy,

Jeffrey W. Pollard

Immunity, Journal Year: 2014, Volume and Issue: 41(1), P. 49 - 61

Published: July 1, 2014

Language: Английский

Citations

3452

New insights into the mechanisms of epithelial–mesenchymal transition and implications for cancer DOI
Anushka Dongre, Robert A. Weinberg

Nature Reviews Molecular Cell Biology, Journal Year: 2018, Volume and Issue: 20(2), P. 69 - 84

Published: Nov. 20, 2018

Language: Английский

Citations

3066

Approaches to treat immune hot, altered and cold tumours with combination immunotherapies DOI
Jérôme Galon, Daniela Bruni

Nature Reviews Drug Discovery, Journal Year: 2019, Volume and Issue: 18(3), P. 197 - 218

Published: Jan. 4, 2019

Language: Английский

Citations

2639

The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014 DOI Creative Commons
Roberto Salgado, Carsten Denkert, Sandra Demaria

et al.

Annals of Oncology, Journal Year: 2014, Volume and Issue: 26(2), P. 259 - 271

Published: Sept. 12, 2014

Language: Английский

Citations

2628

Macrophage Polarization DOI
Peter J. Murray

Annual Review of Physiology, Journal Year: 2016, Volume and Issue: 79(1), P. 541 - 566

Published: Nov. 4, 2016

Macrophage polarization refers to how macrophages have been activated at a given point in space and time. Polarization is not fixed, as are sufficiently plastic integrate multiple signals, such those from microbes, damaged tissues, the normal tissue environment. Three broad pathways control polarization: epigenetic cell survival that prolong or shorten macrophage development viability, microenvironment, extrinsic factors, microbial products cytokines released inflammation. A plethora of advances provided framework for rationally purifying, describing, manipulating polarization. Here, I assess current state knowledge about enumerate major questions regulate physiology tissues.

Language: Английский

Citations

2388

PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations DOI Open Access
Weiping Zou, Jedd D. Wolchok, Lieping Chen

et al.

Science Translational Medicine, Journal Year: 2016, Volume and Issue: 8(328)

Published: March 2, 2016

PD-L1 and PD-1 (PD) pathway blockade is a highly promising therapy has elicited durable antitumor responses long-term remissions in subset of patients with broad spectrum cancers. How to improve, widen, predict the clinical response anti-PD central theme field cancer immunology immunotherapy. Oncologic, immunologic, genetic, biological studies focused on human microenvironment have yielded substantial insight into this issue. Here, we focus tumor evaluate several potential therapeutic markers including expression pattern, genetic mutations within cells neoantigens, epigenetics effector T cell landscape, microbiota. We further clarify mechanisms action these their roles shaping, being shaped, and/or predicting responses. also discuss variety combinations PD scientific rationales for treatment.

Language: Английский

Citations

2140